Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133997) titled 'Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: City of Hope Medical Center
Condition:
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Intervention:
Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Mar...